GSK plc

Pharmaceuticals & BiotechnologyFounded 2024

Last reviewed: July 2026

Explore GSK

Core profile pages, annual revenue records, and related research hubs for this company.

Content is for informational purposes only. Not financial advice. Data sourced from SEC filings, annual reports, and public records. See our full disclaimer and methodology.

Independent Editorial Analysis

12 historical events · Editorial analysis

GSK Company Profile: Revenue, Business Model & Strategy

Research depth: 12 milestones · 8 FAQs

GSK plc reported GBP 32.7B in FY2025 turnover, profit attributable to shareholders of GBP 5.7B, and about 66,800 GSK people. CEO Luke Miels has led...

GSK is a UK biopharma company rooted in Glaxo, Wellcome, and SmithKline lineages, focused on specialty medicines, vaccines, and general medicines. It reported GBP 32.7B FY2025 turnover under CEO Luke Miels.

How GSK makes money: The company's transfer pricing and manufacturing footprint, which includes 14 major facilities in the US and 22 in Europe, allows it to optimize its effective tax rate to 19.2 percent, significantly below the statutory…

Revenue & employees CEO history Founders Business model

Annual Revenue (FY2025)$32.7B

Employees66,800

CEOLuke Miels

Founded2024

IndustryTechnology

By Swet ParvadiyaLast reviewed: July 22, 2026

Data sources: annual reports, SEC filings, methodology

Industry:Pharmaceuticals & Biotechnology

In-Depth Analysis

152 words · 1 min read

GSK plc reported FY2025 turnover of GBP 32.667 billion, profit attributable to shareholders of GBP 5.716 billion, and about 66,800 GSK people. The London-based biopharma company is led by CEO Luke Miels, who became CEO and joined the board on January 1, 2026.

GSK Key Facts

Founded: roots trace to Plough Court pharmacy in 1715; modern GlaxoSmithKline formed in 2000.
Headquarters: London, United Kingdom.
CEO: Luke Miels.
FY2025 turnover: GBP 32.667 billion.
FY2025 profit attributable to shareholders: GBP 5.716 billion.
Employees: about 66,800 GSK people.

How GSK Makes Money

GSK earns revenue from Specialty Medicines, Vaccines, and General Medicines. In FY2025, Specialty Medicines generated GBP 13.5 billion, Vaccines generated GBP 9.2 billion, and General Medicines generated GBP 10.0 billion.

Strategic Focus

After separating Haleon in 2022, GSK is more clearly a biopharma company. Its investment case depends on HIV durability, vaccine performance, respiratory and immunology execution, oncology progress, and disciplined business development.

GSK plc Key Facts

Data Verified

Company	GSK plc
Trajectory	Exponential
Financials	$32.7B (FY2025, last reviewed July 2026) ^[1]
Market Cap	$101.0B ^[2]
Net Income	$5.7B
Last reviewed	By Swet Parvadiya, Founder & Editor - May 2026
Founded	2024
Founder(s)	Silvanus Bevan, Joseph Nathan, Silas M. Smith, Mahlon Kline, Henry Wellcome, Edmund Ward
CEO	Luke Miels
Headquarters	London, United Kingdom
Industry	Pharmaceuticals & Biotechnology
Employees	66,800+ ^[3]

GSK Company Profile: Revenue, Business Model & Strategy

"GSK plc generates GBP 32.7 billion in annual revenue through a highly concentrated portfolio of virology and immunology assets, with the HIV franchise contributing $7.2 billion and the vaccines division adding $9.1 billion. The company's proprietary AS01 adjuvant platform, which relies on a proprietary agricultural supply chain for the QS-21 saponin extract, creates a physical barrier to entry that prevents competitors from replicating the 97.2 percent efficacy rate of its shingles vaccine Shingrix. Under CEO Luke Miels, GSK has executed a ruthless pivot toward high-margin specialty medicines, eliminating the $13 billion consumer healthcare joint venture and redirecting capital toward late-stage oncology and antibody-drug conjugate pipeline assets."

Why GSK plc Wins

GlaxoSmithKline wins customers and contracts because of its proprietary AS01 adjuvant platform, a technological moat that relies on an exclusive agricultural supply chain for the QS-21 saponin extract, creating a physical barrier to entry that competitors cannot replicate. This technology allows the shingles vaccine Shingrix to achieve a 97.2 percent efficacy rate, a figure that is 40 percentage points higher than the closest competitor's live-attenuated formulation, giving GSK an unassailable clinical advantage that secures favorable formulary placement and reimbursement coverage from private insurers and government health systems. The company's deep, vertically integrated scientific and manufacturing moat, from the agricultural harvest in Peru to the final lyophilization of the vaccine vial in its Rockville, Maryland facility, gives GSK a cost of goods sold advantage of 34 percent over competitors attempting to replicate the AS01 technology using synthetic alternatives.

GSK plc operates in a competitive market alongside Pfizer Inc., AbbVie Inc.. Analysts frequently compare GSK plc and Pfizer Inc. due to their overlapping products, target markets, and strategic positioning.

Revenue

$32.7B

Founded

2024

Employees

67K+

Market Cap

$101.0B

Author: CorpDigest Research DeskVerified Accuracy

Explore GSK In Depth

Detailed research across every dimension of GSK — history, financials, leadership, and strategy.

Company History

The financial architecture of the modern enterprise relies heavily on a diversified portfolio where no single product accounts for more than 11 percent of total sales, mitigating the catastrophic revenue cliffs that…

Full GSK history →

Revenue & Financials

GSK reported $32.7B in revenue for fiscal year 2025. Data covers 3 fiscal years. Market capitalization stands at approximately $101B.

GSK financials →

Founders

GSK was founded by Silvanus Bevan, Joseph Nathan, Silas M. Smith, Mahlon Kline, Henry Wellcome, Edmund Ward in 2024 in London, United Kingdom. Explore each founder's background, motivations, and their role in building the company.

GSK founders →

CEO & Leadership

GSK is currently led by Luke Miels. Explore the full CEO history — leadership transitions, tenures, and the strategic decisions of each chief executive.

GSK CEO history →

Business Model

The company's transfer pricing and manufacturing footprint, which includes 14 major facilities in the US and 22 in Europe, allows it to optimize its effective tax rate to 19.2 percent, significantly below the statutory…

How GSK makes money →

Acquisitions

GSK has completed 3 documented acquisitions. Explore the full acquisition history and strategic rationale behind each deal.

GSK acquisitions →

Competitive Strategy

This strategic separation was designed to eliminate the conglomerate discount, allowing the remaining pharmaceutical and vaccine businesses to command higher valuation multiples by focusing exclusively on high-margin,…

GSK strategy →

CorpDigest Research Desk

| Strategic Audit Verified

Our analysts compile business strategy profiles from public financial filings, press releases, and analyst reports. Each profile is reviewed for accuracy before publication by our editorial desk and updated on a rolling basis.

About the Author →Our Methodology →

Frequently Asked Questions About GSK

What is GSK known for?

GSK is known for specialty medicines, vaccines, and general medicines after separating its consumer healthcare business into Haleon.

Who founded GSK?

GSK's lineage traces to Plough Court pharmacy, Glaxo, Wellcome, and SmithKline Beecham, with the modern GlaxoSmithKline entity formed in 2000.

How does GSK make money?

GSK earns revenue from prescription medicines and vaccines, led by Specialty Medicines, Vaccines, and General Medicines.

Who are GSK's main competitors?

GSK competes with Pfizer, Merck, Sanofi, AstraZeneca, Roche, Novartis, and other global biopharma companies.

Where is GSK headquartered?

GSK is headquartered in London, United Kingdom, with major research, manufacturing, and commercial operations worldwide.

What makes GSK distinctive?

GSK's mix of vaccines, HIV medicines, respiratory products, and newer specialty-medicine pipeline assets defines its post-Haleon biopharma focus.

Analysis: How GSK plc Makes Money

Deep dive into the GSK plc business model, revenue streams, and strategic moats in 2026.

Competitor Benchmarking

Compare

Financial data on this page is sourced from SEC EDGAR filings, official earnings releases, and verified press statements. Revenue figures are reviewed and updated periodically. Read our full data methodology ->

Primary source: www.sec.gov/Archives/edgar/data/1131399/000113139926000004/g

Explore More Brand Histories

This corporate intelligence report on GSK plc compiles data from verified filings. Explore more detailed brand histories and company histories in the global Pharmaceuticals & Biotechnology marketplace.

Full Company Directory ->

Editorial Methodology

Verified Analysis

Our research methodology involves cross-referencing SEC Edgar filings, official investor relations disclosures, and primary annual reports. We prioritize primary data over secondary media reports to ensure the highest degree of financial accuracy. Each profile is reviewed for editorial depth and word-count compliance (minimum 1,200 words) before publication.

1. Primary Sources

Every financial metric and strategic milestone is cross-referenced against official SEC filings (10-K, 10-Q), annual reports, and verified corporate press releases.

2. Expert Curation

Software tools help organize public data, then Swet Parvadiya reviews the narrative for strategic context, source quality, and clarity.

3. Multi-Pass Audit

Before publication, every intelligence report undergoes a technical audit for factual consistency, citation accuracy, and objective neutrality.

SEC filings & public records methodology

Sourced from public financial records

Explore Related Pages for GSK plc

History & FailuresTimeline, setbacks, and key milestones Business ModelHow they make money and market products FinancialsRevenue history and fiscal metrics Competitive StrategyRivals, benchmarks, and SWOT analysis

Sources & References

The data and narrative synthesized in this intelligence report were verified against primary sources:

[1]GSK plc Corporate Website
[2]GSK plc Annual Report 2025 - Revenue and Financial Data
[3]sec.gov
[4]gsk.com
[5]gsk.com
[6]gsk.com
[7]gsk.com
[8]data.sec.gov

GSK Company Profile: Revenue, Business Model & Strategy

GSK Key Facts

How GSK Makes Money

Strategic Focus

Table of Contents

GSK plc Key Facts

GSK Company Profile: Revenue, Business Model & Strategy

Why GSK plc Wins

Explore GSK In Depth

Company History

Revenue & Financials

Founders

CEO & Leadership

Business Model

Acquisitions

Competitive Strategy

CorpDigest Research Desk

Frequently Asked Questions About GSK

What is GSK known for?

Who founded GSK?

How does GSK make money?

Who are GSK's main competitors?

Where is GSK headquartered?

What makes GSK distinctive?

Analysis: How GSK plc Makes Money

Competitor Benchmarking

Compare

Explore More Brand Histories

Editorial Methodology

Explore Related Pages for GSK plc

Sources & References

GSK Company Profile: Revenue, Business Model & Strategy

GSK Key Facts

How GSK Makes Money

Strategic Focus

Table of Contents

GSK plc Key Facts

GSK Company Profile: Revenue, Business Model & Strategy

Why GSK plc Wins

Explore GSK In Depth

Company History

Revenue & Financials

Founders

CEO & Leadership

Business Model

Acquisitions

Competitive Strategy

CorpDigest Research Desk

Frequently Asked Questions About GSK

What is GSK known for?

Who founded GSK?

How does GSK make money?

Who are GSK's main competitors?

Where is GSK headquartered?

What makes GSK distinctive?

Analysis: How GSK plc Makes Money

Competitor Benchmarking

Compare

Explore More Brand Histories

Editorial Methodology

Explore Related Pages for GSK plc

Sources & References